Final Analysis of COVID-19 Patients With Inflammatory Bowel Disease in Japan (J-COSMOS): A Multicenter Registry Cohort Study

oleh: Hiroshi Nakase, Yuki Hayashi, Yoshihiro Yokoyama, Takayuki Matsumoto, Minoru Matsuura, Hideki Iijima, Katsuyoshi Matsuoka, Naoki Ohmiya, Shunji Ishihara, Fumihito Hirai, Daiki Abukawa, Tadakazu Hisamatsu, Makoto Sasaki, Masahiro Iizuka, Mikihiro Fujiya, Takayuki Matsumoto, Fukunori Kinjo, Shiro Nakamura, Noriko Kamata, Hideki Iijima, Yuri Etani, Fumiaki Ueno, Sakiko Hiraoka, Takeo Kondo, Takashi Kagaya, Makoto Naganuma, Kiyonori Kobayashi, Taku Kobayashi, Shuji Yamamoto, Yuji Naito, Tadakazu Hisamatsu, Yoki Furuta, Keichi Mitsuyama, Yu Hashimoto, Katsuhiro Arai, Shingo Kato, Itaru Iwama, Motohiro Esaki, Hiroki Tanaka, Hiroshi Nakase, Satoshi Motoya, Atsuo Maemoto, Toshifumi Ashida, Nobuaki Nishimata, Shigeaki Aono, Akira Andoh, Hironori Yamamoto, Shunji Ishihara, Toshiaki Shimizu, Maeda Yasuharu, Kenji Kinoshita, Katuyuki Fukuda, Jun Kato, Ken Takeuchi, Masakazu Nagahori, Masakatsu Fukuzawa, Masayuki Saruta, Takayoshi Suzuki, Michio Itabashi, Masaru Shinozaki, Soichiro Ishihara, Naoki Yoshimura, Katsuyoshi Matsuoka, Yoichi Kakuta, Kenichi Takahashi, Keiichi Tominaga, Ryosuke Sakemi, Sohachi Nanjo, Shusaku Yoshikawa, Keiji Ozeki, Ayako Fuchigami, Takehiko Katsurada, Kenji Watanabe, Hirotake Sakuraba, Fumihito Hirai, Takashi Hisabe, Shigeru Iwase, Naoki Ohmiya, Ryota Hokari, Katsuhiko Nakai, Takeshi Ueda, Daiki Abukawa, Shojiro Yamamoto, Kazutaka Koganei, Reiko Kunisaki, Akira Hokama

Format: Article
Diterbitkan: Elsevier 2023-01-01

Deskripsi

Background and Aims: Japan has experienced 8 waves of the coronavirus disease 2019 (COVID-19) outbreak over the past 3 years, resulting in an increasing number of deaths and incidence of severe infections. This study aimed to analyze the data from the Japanese inflammatory bowel disease (IBD) patients with COVID-19 registry (J-COSMOS) up to the eighth wave to investigate the clinical course of IBD patients with COVID-19 and factors contributing to disease severity. Methods: In this multicenter, observational, cohort study, we analyzed a cohort of 1308 IBD patients diagnosed with COVID-19, enrolled across 77 participating facilities in the J-COSMOS registry from June 2020 to December 2022. Data on age, sex, IBD (classification, treatment, and activity), and COVID-19 (symptoms, severity, and treatment) were analyzed. Results: The majority of patients (76%) were in clinical remission. According to the World Health Organization classification of COVID-19 severity, 98.4% of IBD patients had nonsevere disease, while 1.6% of patients had severe or critical disease. COVID-19 did not affect disease activity in most IBD patients. Stepwise logistic regression analysis revealed that high body mass index, and cerebrovascular disease were risk factors for severe COVID-19. Corticosteroids could affect COVID-19 severity, whereas anti-tumor necrosis factor α antibodies and thiopurines were associated with a reduced risk of severe COVID-19. No deaths were observed among IBD patients with COVID-19 registered in this cohort. Conclusion: The impact of COVID-19 on IBD disease activity and factors associated with COVID-19 severity were consistent with findings of previous reports. No deaths in Japanese patients with IBD were observed.